Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC
Condition: Metastatic Colorectal Adenocarcinoma Interventions: Drug: Fruquintinib; Drug: PD-1 inhibitors; Drug: Trifluridine/Tipiracil; Drug: Bevacizumab Sponsor: Hunan Cancer Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial
Condition: Hepatocellular Carcinoma Intervention: Drug: Sintilimab Sponsor: Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
Conditions: Oncology; Infusion Reaction Interventions: Drug: Nivolumab; Drug: Pembrolizumab; Drug: Ipilimumab; Drug: Durvalumab; Drug: Atezolizumab; Drug: Bevacizumab; Drug: Trastuzumab Sponsor: Isala Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial
Condition: Hepatocellular Carcinoma Intervention: Drug: Sintilimab Sponsor: Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC
Condition: Metastatic Colorectal Adenocarcinoma Interventions: Drug: Fruquintinib; Drug: PD-1 inhibitors; Drug: Trifluridine/Tipiracil; Drug: Bevacizumab Sponsor: Hunan Cancer Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
Conditions: Oncology; Infusion Reaction Interventions: Drug: Nivolumab; Drug: Pembrolizumab; Drug: Ipilimumab; Drug: Durvalumab; Drug: Atezolizumab; Drug: Bevacizumab; Drug: Trastuzumab Sponsor: Isala Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC
Condition: Metastatic Colorectal Adenocarcinoma Interventions: Drug: Fruquintinib; Drug: PD-1 inhibitors; Drug: Trifluridine/Tipiracil; Drug: Bevacizumab Sponsor: Hunan Cancer Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial
Condition: Hepatocellular Carcinoma Intervention: Drug: Sintilimab Sponsor: Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
Conditions: Oncology; Infusion Reaction Interventions: Drug: Nivolumab; Drug: Pembrolizumab; Drug: Ipilimumab; Drug: Durvalumab; Drug: Atezolizumab; Drug: Bevacizumab; Drug: Trastuzumab Sponsor: Isala Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial
Condition: Hepatocellular Carcinoma Intervention: Drug: Sintilimab Sponsor: Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC
Condition: Metastatic Colorectal Adenocarcinoma Interventions: Drug: Fruquintinib; Drug: PD-1 inhibitors; Drug: Trifluridine/Tipiracil; Drug: Bevacizumab Sponsor: Hunan Cancer Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial
Condition: Hepatocellular Carcinoma Intervention: Drug: Sintilimab Sponsor: Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
Conditions: Oncology; Infusion Reaction Interventions: Drug: Nivolumab; Drug: Pembrolizumab; Drug: Ipilimumab; Drug: Durvalumab; Drug: Atezolizumab; Drug: Bevacizumab; Drug: Trastuzumab Sponsor: Isala Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
